A Phase I Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Finding Study to Evaluate the Safety and Pharmacokinetic Profile of LSALT Peptide in Healthy Participants
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2018
At a glance
- Drugs Metablok (Primary)
- Indications Acute kidney injury; Cancer metastases; Sepsis
- Focus Adverse reactions
- Sponsors Arch Biopartners
- 11 Dec 2018 According to a Arch Biopartners media release, the company has formed a subsidiary named Arch Clinical Pty Ltd to conduct this trial. A human trial application process has been started with the Alfred Health Human Research Ethics Committee (HREC). A decision regarding trial approval is expected before February 2019.
- 11 Dec 2018 Status changed from planning to not yet recruiting.
- 29 Oct 2018 According to a Arch Biopartners media release, this trial is expected to begin in early 2019.